Op poisoning treatment
Reading File
Now let me search the medical library for OP poisoning treatment in parallel:
Finding Sources
Finding Sources
Searching PubMed
organophosphate poisoning treatment atropine pralidoxime
Good. Now let me read the key sections from Tintinalli's (best emergency medicine source) and Rosen's for detailed treatment protocols:
Reading File
Reading File
I have excellent content. Let me also grab the Forensic Medicine/Toxicology section for completeness on the specific dosing:
Reading File
Now let me also read the Rosen's antidote therapy section and the decontamination section from Tintinalli's:
Reading File
I now have comprehensive, detailed content from multiple authoritative sources. Here is the full treatment guide:
Organophosphate (OP) Poisoning - Treatment
Mechanism of Toxicity
Organophosphates inhibit acetylcholinesterase (AChE), causing accumulation of acetylcholine (ACh) at:
- Muscarinic receptors - glands, smooth muscle, cardiac
- Nicotinic receptors - neuromuscular junction, sympathetic ganglia
- CNS receptors - seizures, coma
Death is primarily from respiratory failure - bronchorrhea + respiratory muscle paralysis.
Recognizing the Toxidrome
SLUDGE / DUMBELS (muscarinic effects):
| Mnemonic | Symptoms |
|---|---|
| Salivation, Lacrimation, Urination, Defecation/Diaphoresis, GI cramps, Emesis | Classic secretory signs |
| (Killer) Bs | Bronchorrhea, Bronchospasm, Bradycardia |
Nicotinic effects: Muscle fasciculations, weakness, paralysis, tachycardia (may override bradycardia), hypertension, mydriasis
CNS effects: Tremor, headache, confusion, hallucinations, seizures, coma
Treatment: Four Goals
- Decontamination
- Supportive care / airway stabilization
- Reverse ACh excess (Atropine)
- Reverse toxin binding at AChE (Pralidoxime/2-PAM)
Step 1 - Decontamination
- Remove ALL clothing (dermal absorption is a major route) - destroy contaminated clothing
- Flush exposed skin thoroughly with water (preferred); dry agents like flour, sand, or bentonite are alternatives
- Caregivers must wear PPE (full-face air purifier mask, chemical-resistant suit, nitrile/butyl rubber gloves, boots - Level C minimum)
- Gastric lavage and activated charcoal are generally NOT recommended - cholinergics absorb rapidly and profuse vomiting/diarrhea occur early
- Equipment (not skin) can be washed with 5% hypochlorite solution
Step 2 - Supportive Care (Airway Priority)
- Suction secretions and vomitus aggressively
- Provide supplemental O2 and ventilatory support
- Secure airway early if needed
- Avoid succinylcholine if possible - it is metabolized by cholinesterases and can have prolonged effect (4-6 hours) in OP poisoning; prefer rocuronium 1 mg/kg (nondepolarizing, not cholinesterase-metabolized)
- If succinylcholine must be used (1.5 mg/kg), anticipate prolonged sedation and ventilatory support
- Avoid beta-blockers - tachydysrhythmias resolve once cholinergic excess is treated
- Avoid ester anesthetics - may potentiate poisoning
- Treat agitation, seizures, coma with benzodiazepines after airway is secured
Step 3 - Atropine (Antidote #1)
Atropine is a competitive muscarinic receptor antagonist. It blocks muscarinic effects but NOT nicotinic effects (does not reverse paralysis or fasciculations).
Dosing:
| Patient | Initial Dose | Titration |
|---|---|---|
| Adults | 1-3 mg IV | Double every 5 minutes |
| Children | 0.05 mg/kg IV | Double every 5 minutes |
| Severe cases | Up to 200-500 mg in first hour |
- May be given IM if IV/IO access not yet established
- Once controlled: start infusion at 10-20% of total cumulative dose per hour
Endpoint of Atropinization (NOT heart rate or pupil size):
- Drying of respiratory secretions (most important)
- Easing of respiratory effort
- Resolution of bronchospasm/bronchorrhea
Tachycardia and mydriasis may occur at therapeutic doses - do NOT stop therapy for these. Over-atropinization causes anticholinergic toxidrome (hyperthermia, dry flushed skin, urinary retention, delirium).
Step 4 - Pralidoxime / 2-PAM (Antidote #2)
Pralidoxime reactivates AChE by displacing the organophosphate from the enzyme active site. Must be given early - delayed treatment leads to "aging" (irreversible covalent bond between OP and AChE), after which 2-PAM is ineffective.
Dosing:
| Guideline | Dose |
|---|---|
| Rosen's (standard) | 1-2 g IV bolus (25-50 mg/kg in children) |
| WHO recommendation | 30 mg/kg IV bolus, then 8 mg/kg/hr infusion |
| Maintenance | Continue infusion for 24-48 hours; monitor AChE levels |
- Indicated when: hemodynamic instability, large exposures, or requiring large/repeated atropine doses
- NOT recommended for: asymptomatic patients or carbamate exposures with minimal symptoms
- Evidence: theoretical benefit is well-established, though clinical trials have not shown clear mortality reduction (current evidence is inconclusive)
Seizure Management
- Airway protection + oxygen + atropine + benzodiazepines
- Atropine alone may prevent/abort early cholinergic seizures
- Avoid succinylcholine (may mask seizure activity through paralysis)
Special Syndromes
| Syndrome | Timing | Features |
|---|---|---|
| Acute cholinergic crisis | Immediate | Classic SLUDGE/DUMBELS |
| Intermediate syndrome | 1-5 days post-exposure (up to 40% of ingestions) | Proximal limb weakness, neck flexor paralysis, cranial nerve palsies, respiratory muscle paralysis - NO cholinergic signs; needs respiratory support |
| Delayed neuropathy (OPIDN) | Weeks later | Symmetrical sensorimotor axonopathy, leg cramps progressing to weakness/paralysis (mimics Guillain-Barré) |
Adjunct Therapies (Emerging Evidence)
- Magnesium sulfate and calcium channel blockers have some evidence as co-adjuvant treatments (2025 systematic review - PMID 40792609), but are not yet recommended for routine clinical use
- No role for hemodialysis or other enhanced elimination methods
Disposition
| Severity | Disposition |
|---|---|
| Minimal exposure | Decontaminate + observe 6-8 hours in ED |
| Significant poisoning | ICU admission |
| Recovery | Most recover within 10 days if treated early with no anoxic brain injury |
| Fat-soluble OPs | May require prolonged pralidoxime infusion for weeks |
End point of pralidoxime therapy: Absence of signs/symptoms when drug is withheld.
Summary Table: Key Drugs
| Drug | Mechanism | Dose | Treats |
|---|---|---|---|
| Atropine | Competitive muscarinic antagonist | 1-3 mg IV, double q5min; titrate to dry secretions | Muscarinic effects (secretions, bronchospasm, bradycardia) |
| Pralidoxime (2-PAM) | AChE reactivator | 1-2 g IV bolus, then infusion | Nicotinic + muscarinic (if given early) |
| Benzodiazepines | GABA agonist | Standard doses | Seizures |
| Rocuronium | Non-depolarizing NMB | 1 mg/kg | RSI (preferred over succinylcholine) |
Sources: Tintinalli's Emergency Medicine, p. 1343; Rosen's Emergency Medicine, p. 3029; Tietz Textbook of Laboratory Medicine, 7th ed.
Recent evidence note (2025): A meta-analysis (PMID 40792609) found some benefit for magnesium sulfate and/or calcium channel blockers as co-adjuvants, but these are not yet standard of care. The role of pralidoxime in reducing mortality remains controversial per current trials.
This is a shared conversation. Sign in to Orris to start your own chat.